Stock Events

Stock Events

BiomX 

$0.2001
28
+$0.00+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
12.05
52W Low
0.0478
Volume
-
Avg. Volume
4,090
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26MarExpected
Q2 2024
Q3 2024
Q4 2024
-1.1
-0.83
-0.57
-0.31
Expected EPS
-1.095
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-26.17MNet Income

Analyst Ratings

0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to develop therapies similar to BiomX's phage-based treatments.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space, directly competing with BiomX's approach to treating diseases by targeting specific genetic elements.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing field, offering potential competition in developing genetic treatments.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing, a form of gene editing, presenting competition in the precision genetic medicine space.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics specializes in gene therapy, particularly for neurodegenerative diseases, which could compete with BiomX's phage therapy in certain applications.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is working on programmed cellular immunotherapies, a different but competing approach to treating diseases at the genetic level.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is a leader in gene therapy, using its NAV Technology Platform to develop treatments that could compete with BiomX's offerings.

About

BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.
Show more...
CEO
Michael Oster
Employees
20
Country
United States

Listings

XASE
US
PHGE
BOATS
BOATS
PHGE.BOATS

0 Comments

Share your thoughts

FAQ

What is BiomX stock price today?▼
The current price of PHGE-U is $0.20 USD — it has increased by +0% in the past 24 hours. Watch BiomX stock price performance more closely on the chart.
What is BiomX stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange BiomX stocks are traded under the ticker PHGE-U.
What is BiomX revenue for the last year?▼
BiomX revenue for the last year amounts to 0 USD.
What is BiomX net income for the last year?▼
PHGE-U net income for the last year is -26.17M USD.
How many employees does BiomX have?▼
As of September 04, 2026, the company has 20 employees.
In which sector is BiomX located?▼
BiomX operates in the Manufacturing sector.
When did BiomX complete a stock split?▼
BiomX has not had any recent stock splits.
Where is BiomX headquartered?▼
BiomX is headquartered in DOVER, United States.